Pharmaceuticals
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...
2022-04-13 06:00
1771
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administrati...
2022-04-12 20:55
1368
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced today that it has entered into a share subscription agreement with...
2022-04-12 20:00
2069
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...
2022-04-12 15:45
1372
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...
2022-04-12 15:34
2713
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line tr...
2022-04-11 22:07
3357
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
1700
Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation com...
2022-04-11 19:00
2549
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy ...
2022-04-11 18:00
3123
Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Pe...
2022-04-11 16:05
3362
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8-13). Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, April 11, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovativ...
2022-04-11 08:30
4289
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2022-04-11 08:14
3608
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to devel...
2022-04-11 06:51
3196
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study inChina. -- An epidemiology study in China in 2010 showed that there were a...
2022-04-10 18:20
2679
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
BEIJING, April 8, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that they have reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ code: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235)on March 10, for licensin...
2022-04-08 21:00
6859
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
GAITHERSBURG, Md., and PUNE, India, April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ...
2022-04-08 21:00
5901
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3744
AGC to Expand Synthetic Pharmaceutical Production Base in Spain
TOKYO, April 8, 2022 /PRNewswire/ -- AGC Inc. (hereinafter "AGC"), a Tokyo -based world-leading manufacturer of glass, chemicals, high-tech materials, has decided to expand the facilities of AGC Pharma Chemicals Europe S.L.U. (hereinafter "APCE"), an AGC subsidiary in Spain engaged in the syntheti...
2022-04-08 14:00
2387
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
3367
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer (SCLC). This is the first such d...
2022-04-07 22:21
4300
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
6724
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
6354
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
6142
